Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 49

1.

Luspatercept improves hemoglobin levels and blood transfusion requirements in a study of patients with β-thalassemia.

Piga A, Perrotta S, Gamberini MR, Voskaridou E, Melpignano A, Filosa A, Caruso V, Pietrangelo A, Longo F, Tartaglione I, Borgna-Pignatti C, Zhang X, Laadem A, Sherman ML, Attie KM.

Blood. 2019 Mar 21;133(12):1279-1289. doi: 10.1182/blood-2018-10-879247. Epub 2019 Jan 7.

2.

Sotatercept, a novel transforming growth factor β ligand trap, improves anemia in β-thalassemia: a phase II, open-label, dose-finding study.

Cappellini MD, Porter J, Origa R, Forni GL, Voskaridou E, Galactéros F, Taher AT, Arlet JB, Ribeil JA, Garbowski M, Graziadei G, Brouzes C, Semeraro M, Laadem A, Miteva D, Zou J, Sung V, Zinger T, Attie KM, Hermine O.

Haematologica. 2019 Mar;104(3):477-484. doi: 10.3324/haematol.2018.198887. Epub 2018 Oct 18.

3.

Locally acting ACE-083 increases muscle volume in healthy volunteers.

Glasser CE, Gartner MR, Wilson D, Miller B, Sherman ML, Attie KM.

Muscle Nerve. 2018 Jun;57(6):921-926. doi: 10.1002/mus.26113. Epub 2018 Mar 15.

4.

Sotatercept with long-term extension for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes: a phase 2, dose-ranging trial.

Komrokji R, Garcia-Manero G, Ades L, Prebet T, Steensma DP, Jurcic JG, Sekeres MA, Berdeja J, Savona MR, Beyne-Rauzy O, Stamatoullas A, DeZern AE, Delaunay J, Borthakur G, Rifkin R, Boyd TE, Laadem A, Vo B, Zhang J, Puccio-Pick M, Attie KM, Fenaux P, List AF.

Lancet Haematol. 2018 Feb;5(2):e63-e72. doi: 10.1016/S2352-3026(18)30002-4. Epub 2018 Jan 10.

PMID:
29331635
5.

Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study.

Platzbecker U, Germing U, Götze KS, Kiewe P, Mayer K, Chromik J, Radsak M, Wolff T, Zhang X, Laadem A, Sherman ML, Attie KM, Giagounidis A.

Lancet Oncol. 2017 Oct;18(10):1338-1347. doi: 10.1016/S1470-2045(17)30615-0. Epub 2017 Sep 1. Erratum in: Lancet Oncol. 2017 Oct;18(10):e562.

PMID:
28870615
6.

The DART Study: Results from the Dose-Escalation and Expansion Cohorts Evaluating the Combination of Dalantercept plus Axitinib in Advanced Renal Cell Carcinoma.

Voss MH, Bhatt RS, Plimack ER, Rini BI, Alter RS, Beck JT, Wilson D, Zhang X, Mutyaba M, Glasser C, Attie KM, Sherman ML, Pandya SS, Atkins MB.

Clin Cancer Res. 2017 Jul 15;23(14):3557-3565. doi: 10.1158/1078-0432.CCR-16-2395. Epub 2016 Dec 28.

7.

A phase 2 study of dalantercept, an activin receptor-like kinase-1 ligand trap, in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.

Jimeno A, Posner MR, Wirth LJ, Saba NF, Cohen RB, Popa EC, Argiris A, Grossmann KF, Sukari A, Wilson D, Zhang X, Sun J, Glasser C, Attie KM, Sherman ML, Pandya SS, Weiss J.

Cancer. 2016 Dec 1;122(23):3641-3649. doi: 10.1002/cncr.30317. Epub 2016 Sep 20.

8.

Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: Results of a randomized, placebo-controlled clinical trial.

Campbell C, McMillan HJ, Mah JK, Tarnopolsky M, Selby K, McClure T, Wilson DM, Sherman ML, Escolar D, Attie KM.

Muscle Nerve. 2017 Apr;55(4):458-464. doi: 10.1002/mus.25268. Epub 2016 Dec 23.

PMID:
27462804
9.

A phase 1 study of ACE-536, a regulator of erythroid differentiation, in healthy volunteers.

Attie KM, Allison MJ, McClure T, Boyd IE, Wilson DM, Pearsall AE, Sherman ML.

Am J Hematol. 2014 Jul;89(7):766-70. doi: 10.1002/ajh.23732. Epub 2014 Apr 26.

10.

Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of dalantercept, an activin receptor-like kinase-1 ligand trap, in patients with advanced cancer.

Bendell JC, Gordon MS, Hurwitz HI, Jones SF, Mendelson DS, Blobe GC, Agarwal N, Condon CH, Wilson D, Pearsall AE, Yang Y, McClure T, Attie KM, Sherman ML, Sharma S.

Clin Cancer Res. 2014 Jan 15;20(2):480-9. doi: 10.1158/1078-0432.CCR-13-1840. Epub 2013 Oct 30.

11.

A single ascending-dose study of muscle regulator ACE-031 in healthy volunteers.

Attie KM, Borgstein NG, Yang Y, Condon CH, Wilson DM, Pearsall AE, Kumar R, Willins DA, Seehra JS, Sherman ML.

Muscle Nerve. 2013 Mar;47(3):416-23. doi: 10.1002/mus.23539. Epub 2012 Nov 21.

PMID:
23169607
12.

Abnormal growth in noonan syndrome: genetic and endocrine features and optimal treatment.

Padidela R, Camacho-Hübner C, Attie KM, Savage MO.

Horm Res. 2008;70(3):129-36. doi: 10.1159/000145016. Epub 2008 Jul 29. Review.

13.

Relationship between insulin sensitivity and IGF-I sensitivity in low birth weight prepubertal children.

Román R, Iñiguez G, Salazar T, Avila A, Barrera A, Mericq V, Attie KM, Cassorla F.

Horm Res. 2008;70(2):73-8. doi: 10.1159/000139147. Epub 2008 Jun 12.

PMID:
18547952
14.

Endocrine assessment, molecular characterization and treatment of growth hormone insensitivity disorders.

Savage MO, Attie KM, David A, Metherell LA, Clark AJ, Camacho-Hübner C.

Nat Clin Pract Endocrinol Metab. 2006 Jul;2(7):395-407. Review.

PMID:
16932322
15.

Efficacy of a long-acting growth hormone (GH) preparation in patients with adult GH deficiency.

Hoffman AR, Biller BM, Cook D, Baptista J, Silverman BL, Dao L, Attie KM, Fielder P, Maneatis T, Lippe B; Genentech Adult Growth Hormone Deficiency Study Group.

J Clin Endocrinol Metab. 2005 Dec;90(12):6431-40. Epub 2005 Sep 13.

PMID:
16159930
16.

Efficacy and safety results of long-term growth hormone treatment of idiopathic short stature.

Kemp SF, Kuntze J, Attie KM, Maneatis T, Butler S, Frane J, Lippe B.

J Clin Endocrinol Metab. 2005 Sep;90(9):5247-53. Epub 2005 Jul 5.

PMID:
15998780
17.

Pharmacokinetic and pharmacodynamic characteristics of a long-acting growth hormone (GH) preparation (nutropin depot) in GH-deficient children.

Kemp SF, Fielder PJ, Attie KM, Blethen SL, Reiter EO, Ford KM, Marian M, Dao LN, Lee HJ, Saenger P.

J Clin Endocrinol Metab. 2004 Jul;89(7):3234-40.

PMID:
15240597
18.

Growth hormone (GH) dose-response in young adults with childhood-onset GH deficiency: a two-year, multicenter, multiple-dose, placebo-controlled study.

Underwood LE, Attie KM, Baptista J; Genentech Collaborative Study Group.

J Clin Endocrinol Metab. 2003 Nov;88(11):5273-80.

PMID:
14602761
19.

The pharmacokinetic and pharmacodynamic characteristics of a long-acting growth hormone (GH) preparation (nutropin depot) in GH-deficient adults.

Cook DM, Biller BM, Vance ML, Hoffman AR, Phillips LS, Ford KM, Benziger DP, Illeperuma A, Blethen SL, Attie KM, Dao LN, Reimann JD, Fielder PJ.

J Clin Endocrinol Metab. 2002 Oct;87(10):4508-14.

PMID:
12364427
20.

A long-acting human growth hormone (Nutropin Depot): efficacy and safety following two years of treatment in children with growth hormone deficiency.

Silverman BL, Blethen SL, Reiter EO, Attie KM, Neuwirth RB, Ford KM.

J Pediatr Endocrinol Metab. 2002 May;15 Suppl 2:715-22.

PMID:
12092685
21.

Assessing insulin resistance: application of a fasting glucose to insulin ratio in growth hormone-treated children.

Burgert TS, Vuguin PM, DiMartino-Nardi J, Attie KM, Saenger P.

Horm Res. 2002;57(1-2):37-42.

PMID:
12006718
22.

A multicenter study of the efficacy and safety of sustained release GH in the treatment of naive pediatric patients with GH deficiency.

Reiter EO, Attie KM, Moshang T Jr, Silverman BL, Kemp SF, Neuwirth RB, Ford KM, Saenger P; Genentech, Inc.-Alkermes, Inc. Collaborative Study Group.

J Clin Endocrinol Metab. 2001 Oct;86(10):4700-6.

PMID:
11600528
23.

Effect of long-term recombinant growth hormone therapy in children--the National Cooperative Growth Study, USA, 1985-1994.

Root AW, Kemp SF, Rundle AC, Dana K, Attie KM.

J Pediatr Endocrinol Metab. 1998;11(3):403-12.

PMID:
11517956
24.

The importance of growth hormone replacement therapy for bone mass in young adults with growth hormone deficiency.

Attie KM.

J Pediatr Endocrinol Metab. 2000 Sep;13 Suppl 2:1011-21. Review.

PMID:
11086656
26.

Genetic studies in idiopathic short stature.

Attie KM.

Curr Opin Pediatr. 2000 Aug;12(4):400-4. Review.

PMID:
10943824
27.

Growth hormone therapy of Turner syndrome: the impact of age of estrogen replacement on final height. Genentech, Inc., Collaborative Study Group.

Chernausek SD, Attie KM, Cara JF, Rosenfeld RG, Frane J.

J Clin Endocrinol Metab. 2000 Jul;85(7):2439-45.

PMID:
10902791
28.

Role of oestrogen therapy in the management of short stature in Turner syndrome.

Chernausek SD, Attie KM.

Acta Paediatr Suppl. 1999 Dec;88(433):130-2.

PMID:
10626564
29.
30.

Metabolic consequences of 5-year growth hormone (GH) therapy in children treated with GH for idiopathic short stature. Genentech Collaborative Study Group.

Saenger P, Attie KM, DiMartino-Nardi J, Hintz R, Frahm L, Frane JW.

J Clin Endocrinol Metab. 1998 Sep;83(9):3115-20.

PMID:
9745413
31.

Treatment of glucocorticoid-induced growth suppression with growth hormone. National Cooperative Growth Study.

Allen DB, Julius JR, Breen TJ, Attie KM.

J Clin Endocrinol Metab. 1998 Aug;83(8):2824-9.

PMID:
9709954
32.

Growth hormone treatment of girls with Turner syndrome: the National Cooperative Growth Study experience.

Plotnick L, Attie KM, Blethen SL, Sy JP.

Pediatrics. 1998 Aug;102(2 Pt 3):479-81.

PMID:
9685447
33.

Growth hormone therapy of Turner's syndrome: beneficial effect on adult height.

Rosenfeld RG, Attie KM, Frane J, Brasel JA, Burstein S, Cara JF, Chernausek S, Gotlin RW, Kuntze J, Lippe BM, Mahoney CP, Moore WV, Saenger P, Johanson AJ.

J Pediatr. 1998 Feb;132(2):319-24.

PMID:
9506648
36.
37.

Overview of the National Cooperative Growth Study substudy of serial growth hormone measurements.

Blethen SL, Breen TJ, Attie KM.

J Pediatr. 1996 May;128(5 Pt 2):S38-41.

PMID:
8627467
38.

Mutations of the growth hormone receptor--widening the search.

Attie KM.

J Clin Endocrinol Metab. 1996 May;81(5):1683-5. No abstract available.

PMID:
8626814
39.
40.

Mutations of the growth hormone receptor in children with idiopathic short stature. The Growth Hormone Insensitivity Study Group.

Goddard AD, Covello R, Luoh SM, Clackson T, Attie KM, Gesundheit N, Rundle AC, Wells JA, Carlsson LM.

N Engl J Med. 1995 Oct 26;333(17):1093-8.

41.
42.

Recombinant human growth hormone in infants and young children with chronic renal insufficiency. Genentech Collaborative Study Group.

Fine RN, Attie KM, Kuntze J, Brown DF, Kohaut EC.

Pediatr Nephrol. 1995 Aug;9(4):451-7.

PMID:
7577408
43.

The timing of sexual maturation in a group of US white youths.

Roche AF, Wellens R, Attie KM, Siervogel RM.

J Pediatr Endocrinol Metab. 1995 Jan-Mar;8(1):11-8.

PMID:
7584691
44.

Reduced concentration of serum growth hormone-binding protein in children with idiopathic short stature. National Cooperative Growth Study.

Carlsson LM, Attie KM, Compton PG, Vitangcol RV, Merimee TJ.

J Clin Endocrinol Metab. 1994 Jun;78(6):1325-30.

PMID:
8200933
45.

Growth response of children with non-growth-hormone deficiency and marked short stature during three years of growth hormone therapy.

Hopwood NJ, Hintz RL, Gertner JM, Attie KM, Johanson AJ, Baptista J, Kuntze J, Blizzard RM, Cara JF, Chernausek SD, et al.

J Pediatr. 1993 Aug;123(2):215-22.

PMID:
8345416
46.

Six-year results of a randomized, prospective trial of human growth hormone and oxandrolone in Turner syndrome.

Rosenfeld RG, Frane J, Attie KM, Brasel JA, Burstein S, Cara JF, Chernausek S, Gotlin RW, Kuntze J, Lippe BM, et al.

J Pediatr. 1992 Jul;121(1):49-55.

PMID:
1625092
47.

Stage-specific binding of inhibin and activin to subpopulations of rat germ cells.

Woodruff TK, Borree J, Attie KM, Cox ET, Rice GC, Mather JP.

Endocrinology. 1992 Feb;130(2):871-81.

PMID:
1310280
48.

Activin stimulates spermatogonial proliferation in germ-Sertoli cell cocultures from immature rat testis.

Mather JP, Attie KM, Woodruff TK, Rice GC, Phillips DM.

Endocrinology. 1990 Dec;127(6):3206-14.

PMID:
2249646
49.

The pubertal growth spurt in eight patients with true precocious puberty and growth hormone deficiency: evidence for a direct role of sex steroids.

Attie KM, Ramirez NR, Conte FA, Kaplan SL, Grumbach MM.

J Clin Endocrinol Metab. 1990 Oct;71(4):975-83.

PMID:
2401720

Supplemental Content

Loading ...
Support Center